116526 ⎘
Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2); Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1) Beta-glucuronidase (3.2.1.31)
SIALYLATED GLYCOPROTEIN COMPOSITION AND USES THEREOF
#2USE OF MULTITARGETED POLYPEPTIDE IN TREATMENT OF ORGAN FIBROSIS
#3SELECTIVE FUNCTIONAL ENHANCEMENT OF STEM CELLS AND OR THEIR GENETIC MATERIAL, WITH GENE TRANSFECTION FOR SHORT-AND LONG-TERM TREATMENT OF AGE-RELATED DISEASE STATES
#4ENGINEERED ALPHA KLOTHO POLYPEPTIDES AND USES THEREOF
#5PLANT REGULATORY ELEMENTS AND USES THEREOF
#6COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES
#7METHODS AND COMPOSITIONS FOR IMPROVED COGNITION
#8METHODS FOR TREATING INHERITED METABOLIC DISORDERS
#9ENGINEERED ALPHA KLOTHO POLYPEPTIDES AND USES THEREOF
#10SYSTEMS FOR MODULATING DRUG METABOLISM BY CELLS, METHODS AND COMPOSITIONS THEREOF
#11ENHANCING ABSORPTION OF DIETARY COMPOUNDS TO PROMOTE HEALTH
#12GLUCOSE SENSORS AND METHODS OF USE THEREOF
#13SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND BEHAVIOUR IMPAIRMENTS
#14SECRETED SPLICING VARIANT OF MAMMAL KLOTHO AS A MEDICAMENT FOR COGNITION AND BEHAVIOUR IMPAIRMENTS
#15PRODUCTS AND METHODS FOR ASSESSING AND INCREASING KLOTHO PROTEIN LEVELS
#16FIBROBLAST GROWTH FACTOR 23 MODULATING COMPOUNDS
#17PLANT REGULATORY ELEMENTS AND USES THEREOF
#18SECRETED SPLICING VARIANT OF KLOTHO FOR TREATING BONE DISORDERS
#19SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
#20Methods and compositions for improved cognition
#21PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE
#22B-GLUCURONIDASE PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE
#23Plant regulatory elements and uses thereof
#24Chimeric and other variant β-glucuronidase enzymes with enhanced properties
#25CROSS-LINKING COMPOUNDS AND METHODS OF USE THEREOF
#26SIALYLATED GLYCOPROTEIN COMPOSITONS AND USES THEREOF
#27Enzymatic mutant suitable for homogeneous immunoassay method
#28Compositions of beta-glucuronidase enzyme blends with enhanced enzymatic activity and methods of preparation thereof
#29GENETICALLY MODIFIED MESENCHYMAL STEM CELL EXPRESSING KLOTHO
#30Process to produce Klotho protein in vitro
#31Glucose sensors and methods of use thereof
#32Products and Methods for Assessing and Increasing Klotho Protein Levels
#33METHODS AND MATERIALS FOR TREATING OSTEOARTHRITIS
#34Proteins having pneumococcal capsule degrading activity and methods of use
#35Plant regulatory elements and uses thereof
#36Methods and compositions for improved cognition
#37Soluble alpha-Klotho proteins, protein fragments, and uses thereof
#38having antimicrobial effect on and
#39SIALYLATED GLYCOPROTEIN COMPOSITONS AND USES THEREOF
#40Methods and compositions for improved cognition
#41Mutant FGF21 polypeptide compositions
#42Chimeric and other variant beta-glucuronidase enzymes with enhanced properties
#43Compositions of beta-glucuronidase enzyme blends with enhanced enzymatic activity and methods of preparation thereof
#44THERMOSTABILE BETA-GLUCURONIDASE FORMULATIONS
#45DELIVERY OF dsRNA TO ARTHROPODS
#46Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
#47METHODS AND VECTORS FOR TREATING CNS DISORDERS
#48PRODUCTS AND METHODS FOR ASSESSING AND INCREASING KLOTHO PROTEIN LEVELS
#49Plant regulatory elements and uses thereof
#50Nucleic acids encoding antibodies with high affinity for Alpha-Klotho
#51SIALYLATED GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
#52Secreted splicing variant of mammal Klotho as a medicament for cognition and behaviour impairments
#53Methods and compositions for recombinase-based genetic diversification
#54Method for immobilization of glucuronidase enzymes for the detection of products derived from glucuronide compounds
#55INHIBITING GENE EXPRESSION WITH dsRNA
#56Engineered enzyme for enzyme replacement therapy
#57ASSISTED ENZYME REPLACEMENT THERAPY
#58Methods and compositions for improved cognition
#59Plant regulatory elements and uses thereof
#60Nanoparticles containing extracellular matrix for drug delivery
#61Nucleic acid sequence for protein expression
#62Methods and means for obtaining modified phenotypes
#63GENETICALLY MODIFIED MESENCHYMAL STEM CELL EXPRESSING KLOTHO
#64Soluble alpha klotho and serum albumin fusion protein
#65Methods and compositions for improved cognition
#66Sialylated glycoprotein compositions and uses thereof
#67Mutant lactobacillus beta-glucuronidase enzymes with enhanced enzymatic activity
#68Delivery of dsRNA to arthropods
#69Inactivation of off-taste inducing enzymes
#70METHODS AND COMPOSITIONS USING KLOTHO-FGF FUSION POLYPEPTIDES
#71Antibodies with high affinity for alpha-Klotho
#72Human Antigen Binding Proteins That Bind To a Complex Comprising beta-Klotho and an FGF Receptor
#73Anti-FGFR1c antibody-FGF21 fusion proteins
#74METHODS AND COMPOSITIONS USING FGF23 VARIANT POLYPEPTIDES
#75METHODS OF MONITORING ADHERENCE TO HALOPERIDOL THERAPY
#76Sialylated glycoprotein compositons and uses thereof
#77Methods and means for obtaining modified phenotypes
#78Mutant beta-glucuronidase enzymes with enhanced enzymatic activity
#79Apparatuses and methods for high-throughput protein synthesis
#80Mutant β-glucuronidase enzymes with enhanced enzymatic activity
#81Use of at least one chromogenic and/or fluorogenic phosphatase substrate for the detection and/or enumeration of enterobacteria in a sample
#82siRNA-mediated gene silencing
#83GUARD CELL EXPRESSION CASSETTES COMPOSITIONS AND METHODS OF USE THEREOF
#84ADENO-ASSOCIATED VIRUS VECTORS AND METHODS OF USE THEREOF
#85Sialylated glycoprotein compositions and uses thereof
#86Delivery of dsRNA to arthropods
#87Stem-specific promoter from sugarcane dirigent gene
#88Sialylated glycoprotein compositions and uses thereof
#89Klotho variant polypeptides
#90Delivery of dsRNA to arthropods
#91ENZYME REPLACEMENT THERAPY FOR TREATING MPS VII RELATED BONE LESIONS USING A CHEMICALLY MODIFIED ENZYME
#92Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
#93Pharmaceutical composition for treating lysosomal storage disease
#94Methods and compositions using Klotho-FGF fusion polypeptides
#95SiRNA-mediated gene silencing
#96MODIFIED ENZYME TREATMENT METHOD
#97Biological systems input-output response system and plant sentinels
#98Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
#99Delivery of dsRNA to arthropods
#100Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
#101Methods and means for obtaining modified phenotypes
#102INACTIVATION OF OFF-TASTE INDUCING ENZYMES
#103Methods and means for obtaining modified phenotypes
#104Assisted enzyme replacement therapy
#105Delivery of dsRNA to arthropods
#106DELIVERY OF THERAPEUTIC AGENTS TO THE BONE
#107Prenatal enzyme replacement therapy for hypophosphatasia
#108SiRNA-mediated gene silencing
#109METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES
#110Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from and related organisms, methods
#111RNA interference suppresion of neurodegenerative diseases and methods of use thereof
#112Compositions, methods and kits for biarsenical fluorophore labeling
#113Compositions and Methods for Treating Lysosomal Storage Diseases
#114siRNA-MEDIATED GENE SILENCING WITH VIRAL VECTORS
#115Method for screening a test substance for activating a receptor associated with FGF 21 activity
#116Enhancing the effect of therapeutic proteins on the central nervous system
#117Human beta-glucuronidase mutants with elevated enzymatic activity under physiological conditions and method for identifying such
#118SPORE SURFACE DISPLAYS OF BIOACTIVE MOLECULES
#119Delivery of therapeutic agents to the bone
#120Methods and compositions using Klotho-FGF fusion polypeptides
#121Biological systems input-output response system and plant sentinels
#122MODIFIED ENZYME AND TREATMENT METHOD
#123Inhibiting Gene Expression with dsRNA
#124Inhibiting Gene Expression with dsRNA
#125Allele-specific silencing of disease genes
#126MEMBRANE BOUND REPORTER GENE SYSTEM
#127METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT
#128Chimeral polypeptide composition for cross-placenta delivery
#129ENHANCING THE EFFECT OF THERAPEUTIC PROTEINS ON THE CENTRAL NERVOUS SYSTEM
#130Beta-glucuronidase with an attached short peptide of acidic amino acids
#131Methods and means for obtaining modified phenotypes
#132Fusion proteins for prodrug activation
#133Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
#134siRNA-Mediated gene silencing with viral vectors
#135Genetically purified gellan gum
#136Negative-sense RNA virus vector for nerve cell
#137Methods and means for obtaining modified phenotypes
#138Enveloped miroorganism
#139Compositions, methods and kits for biarsenical fluorophore labeling
#140Reporter gene
#141Cytoplasmic inhibition of gene expression
#142Negative-sense RNA virus vector for nerve cell
#143Fungal beta-glucuronidase genes and gene products
#144Production of lysosomal enzymes in plants by transient expression
#145Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in
#146Delivery of dsRNA to arthropods
#147RNA interference suppresion of neurodegenerative diseases and methods of use thereof